Marshall Wace North America’s Alder Biopharmaceuticals ALDR Stock Holding History

Marshall Wace North America’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-125,114	Closed	-$2.36M	–	1761
2019 Q3	$2.36M	Buy	+125,114	New	+$1.43M	0.01%	515
2017 Q4	–	Sell	-81,681	Closed	-$980K	–	1742
2017 Q3	$980K	Buy	+81,681	New	+$852K	0.01%	956
2017 Q2	–	Sell	-211,913	Closed	-$4.45M	–	1529
2017 Q1	$4.45M	Buy	+211,913	New	+$4.69M	0.04%	420

Marshall Wace North America's ALDR Position: Q4 2019 in Review

Marshall Wace North America sold out of Alder Biopharmaceuticals (ALDR) in Q4 2019, closing a stake of 125,114 shares — an estimated $2.36M sold.

Marshall Wace North America first reported a position in ALDR in Q1 2017 and held it in 3 quarters. The position peaked at $4.45M in Q1 2017. 0 funds tracked by Wall St. Rank hold ALDR as of Q4 2019.

Marshall Wace North America reported no remaining Alder Biopharmaceuticals position as of Q4 2019 after selling out during the quarter.
Marshall Wace North America sold 125,114 Alder Biopharmaceuticals shares in Q4 2019, an estimated $2.36M.
Marshall Wace North America first reported a position in Alder Biopharmaceuticals in Q1 2017 and held it in 3 quarters.
Marshall Wace North America's Alder Biopharmaceuticals position peaked at $4.45M in Q1 2017.
0 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2019.

Based on Marshall Wace North America's 13F filing for Q4 2019, filed 14 Feb 2020.